

ANTIGENICS INC /DE/

Form 8-K

July 27, 2010

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

July 27, 2010

Date of Report (Date of earliest event reported)

**ANTIGENICS INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**

**000-29089**

**06-1562417**

(State or other jurisdiction (Commission (IRS Employer

of incorporation)

File Number) Identification No.)

**3 Forbes Road**

**Lexington, MA**

**02421**

(Address of principal executive offices)

(Zip  
Code)

**781-674-4400**

(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 7.01 Regulation FD Disclosure**

On July 27, 2010, Antigenics Inc. announced positive results with AG-707, an investigational therapeutic vaccine being developed to treat herpes simplex virus-2 (HSV-2), the virus that causes genital herpes, in infected patients. Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4<sup>+</sup> and CD8<sup>+</sup> T cells. In this four-arm, phase 1 study, 35 HSV-2 seropositive patients received AG-707+QS-21 Stimulon<sup>®</sup> adjuvant (Antigenics proprietary saponin adjuvant), AG-707 alone, QS-21 alone, or placebo. All patients who were evaluable for immune response and received AG-707 with QS-21 showed a statistically significant CD4<sup>+</sup> T cell response (100%; 7/7) to HSV-2 antigens as detected by IFN- $\gamma$  Elispot, and the majority of those patients demonstrated a CD8<sup>+</sup> T cell response (63%; 5/8). This study is the first to demonstrate that heat shock proteins complexed to viral antigens induce an antigen-specific T cell response in humans.

The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated July 27, 2010

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANTIGENICS INC.**

Date: July 27, 2010 By: /s/ Shalini Sharp

Shalini Sharp  
Chief Financial Officer

---

EXHIBIT INDEX

Exhibit No.   Description of Exhibit

99.1            Press Release dated July 27, 2010